Jayaweera DT, Campa A, Casillas VJ, Martinez SS, Shin DH, Li Y, Young S, Baum MK.

Slides:



Advertisements
Similar presentations
Hepatitis B & Hepatitis C in HIV
Advertisements

HBV and HIV HIV and HBV VG Naidoo Gastroenterology.
Hcv infection and management in advanced liver disease
Alfredo ALBERTI. How to predict outcome in hepatitis C patients Alfredo Alberti Department of Clinical and Experimental Medicine Venetian Institute of.
Diagnostic Accuracy of Serum Hyaluronic Acid for Advanced Fibrosis/Cirrhosis in Patients Coinfected with HIV and HCV S. Resino,* 1 P. Miralles, 2 D. Micheloud,
BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.
CORRELATION BETWEEN HBSAG LEVEL AND VIRAL LOAD
V. Petrenkiene*, D. Petrauskas L. Kupcinskas, Lithuanian University of Health sciences Clinic of Gastroenterology Kaunas Utility of non-invasive markers.
Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,
The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.
Anti-oxidant status in patients with Rheumatoid Arthritis after Spa Therapy Dr. Mine Karagülle.
National Hepatitis C Database Dr Lelia Thornton Health Protection Surveillance Centre December 2012.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Viruses and Cancer.
Factors associated with IL-6 levels during HIV infection Álvaro Borges, Jemma O’Connor, Andrew Phillips, Frederikke Rönsholt, Sarah Pett, Michael Vjecha,
Results Table 1: Factors associated with advanced liver fibrosis in univariable analysis among 216 chronic HCV patients Background There is a clinical.
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
ADAP ADVOCACY ASSOCIATION 2013 HIV/HCV CO-INFECTION ADAP SUMMIT ROBERT L. CALDWELL, PH.D. A MEDICAL PERSPECTIVE ON HIV/HCV CO- INFECTION HIV and Hepatitis.
Impact of weight management in chronic HCV Egyptian patients on liver fibrosis. By: Dr. Osama A. Fekry Lecturer of CN at the AUC Head of clinical Nutrition.
Interpreting Your Biopsy and Lab Results
Renal Transplantation for HIV/HCV Co-infected Patients Solid Organ Transplantation and People With HIV: Ethics and Policy Conference David Oldach & Robert.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Evaluation of Liver Histology in Clinical Trials for Chronic Viral Hepatitis Zachary Goodman, M.D., Ph.D. Chief, Hepatic Pathology Armed Forces Institute.
Patient Information - Viral Hepatitis B (HBV)
Twice Weekly Peg-IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy Among HIV/HCV Co-Infected African American Patients Alison.
The Relation of Interleukin 6 Gene-190 T/C Polymorphisms with Anthropometric and Biochemical Characteristics in a group of Obese Children Authors: Mărginean.
HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.
Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,
Sources of Hepatitis C Infection (U.S.) Previously Acquired (
W24 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve Early fibrosis to compensated cirrhosis No HBV or HIV co-infection N = 10 SOF + weight-based.
Asselah T. AASLD 2015, Abs OSIRIS  Design SMV + PEG-IFN + RBV Open label Chronic HCV infection Genotype 4 Treatment-naïve Mild to moderate fibrosis.
Date of download: 6/1/2016 From: Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons Ann Intern Med. 2016;164(2): doi: /M
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
Advanced Glycation End Products and Antioxidant Status in Type 2 Diabetic Patients With and Without Peripheral artery disease Annunziata Lapolla; Francesco.
The Geography of Viral Hepatitis C In Texas, Mara Hedrich
The Natural History of Liver Fibrosis Progression Rate in Hepatitis C Infection David Yamini, Benjamin Basseri, Anush Arakelyan, Pedram Enayati, Tram T.
Iron, Cholesterol, and Cancer Brian J. Wells, MD, MS The Cleveland Clinic Foundation.
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
Setting the Scene. Non A, non B Hepatitis  Early 1970’s recognised that 2/3 of post transfusional hepatitis were –ve for both Hep A & Hep B Non Hep A.
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
Henry Masur, MD Bethesda, Maryland
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients with Unfavorable Treatment Characteristics A Randomized Clinical Trial JAMA. 2013;310(8):
Hepatitis C.
No conflict of interest
Stacey B Trooskin MD PhD
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
4th IAS Conference , Sydney, Australia, July 2007
Dr Iyat Abdul Sattar A study on the clinical & serolological markers of HBV among patients with chronic HBV infection in Babylon Dr Monem Makki Alshok.
FRAX & ITS ASSOCIATIONS IN RHEUMATOID ARTHRITIS
Miss.Shuchismita Behera Miss.Sujata Dixit Dr.G.Bulliyya Dr.S.K.Kar
ARV-trial.com RUBY-I Study, cohort 2: ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV for HCV genotype 1 with renal impairment Design Open label W12.
Underwriting Screening Liver Test Abnormalities:
Supplementary Table 1. Dissociation cases of EI and Fibrosis Case 1 2
Chronic Kidney Disease in HIV Infection: An Urban Epidemic
The Aging Liver in the Aging HIV and HCV Patients
Gianluca Tell, Carlo Vascotto, Claudio Tiribelli  Journal of Hepatology 
Evaluation of the Patient With HCV Infection
Clinical outcome after SVR: ANRS CO22 HEPATHER
Volume 153, Issue 5, Pages e2 (November 2017)
Impact of metabolic risk factors on HCC
Hepatitis C: After the Diagnosis
Cholesterol Management in HIV-infected and Uninfected Patients: The Veterans Aging Cohort Study Leaf, DA, Goulet J, Goetz MB, Oursler KA, Gilbert C, Frieberg.
VACS Scientific Meeting October 15, 2008 Joseph K. Lim, M.D.
Volume 125, Issue 2, Pages (August 2003)
Incidence of HCC after HCV treatment with DAAs: ERCHIVES
Core Competency 1: Epidemiologic Background of HIV/HCV Co-infection in the United States Lesson 2: Morbidity and Mortality in HCV Co-infected People Living.
Correlations between indices of oxidative status and individual condition. Correlations between indices of oxidative status and individual condition. Lines.
Presentation transcript:

Jayaweera DT, Campa A, Casillas VJ, Martinez SS, Shin DH, Li Y, Young S, Baum MK

Background  Patients co-infected with HIV/HCV compared to those infected with HCV alone have: Higher levels of HCV-RNA. An accelerated progression to liver disease. More rapid development of liver fibrosis and cirrhosis. Greater morbidity and mortality Kim A, et al., Rotman Y et al., Pascual-Pareja J et al., Sulkowski MS Monga HK et al., Maciás et al., 2009.

Background  HCV infection characterized by oxidative stress generated by chronic inflammation. 7,8  Limited data available on HIV/HCV co-infection.  HIV and HCV independently regulate hepatic fibrosis progression through generation of reactive oxygen species (ROS). 9  HCV core protein localizes to mitochondria and its expression causes inhibition of electron transport, ROS production & glutathione Yadav D et al, Choi J & Ou J, Lin W et al, Korenaga M. et al., 2005

Background  As HCV disease progresses: Lipid peroxidation products are and glutathione is in serum, PBMC & liver specimens. 11,12 Antioxidant micronutrients are depleted in serum and liver biopsy specimens. 8 Decreased liver micronutrient antioxidant levels are associated with increased liver fibrosis Baum MK et al., Mahmood S et al 2004.

Background  Oxidative stress is determined by levels of malondialdehyde (MDA), glutathione, 17,18 & the extent of mtDNA damage. 22  MDA, an index of lipid peroxidation, is in liver, serum, erythrocytes and PBMC in liver diseases, 19 correlates with HCV disease activity 18 & fibrosis staging. 17,20  MDA is inversely correlated with hepatic and plasma reduced glutathione De Maria N et al., Ko WS et al., Malvy DJM, et al Serejo F, et al., Barbaro G, et al., Fromenty B et al., 1997.

Background  Glutathione is the most abundant non- enzymatic antioxidant in cells. 22  Reduced glutathione (GSH) determines the extent of oxidative capacity.  Oxidized glutathione (GSSG) with severity of HCV, indicating increased oxidative stress & decreased antioxidative capacity Akerboom TP et al., Wu G et al., 2004.

Background  Oxidative damage of mtDNA leads to base modification, misreading during replication, and point mutations. 24  The most common form of mtDNA oxidative damage, is increase in the amount of mt- specific 8-oxo-dG. 25  Mt-specific 8-oxo-dG strongly correlates with markers of systemic oxidative stress & is a risk factor for hepatocellular carcinoma Fromenty B et al., Dagon T et al., Gerschenson M et al., Aukurst P et al., Wu G et al., Barbaro G et al., Chuma M et al, 2008.

Preliminary Study  HIV/HCV-co-infected compared to HIV- mono-infected participants had: Higher plasma MDA (1.897±0.835 vs ±0.223 nmol/mL, p=0.006). Lower plasma antioxidant concentrations: ○ Vitamin A (39.5±14.1 vs. 52.4±16.2 mg/dL, p=0.0004). ○ Vitamin E (8.29±2.1 vs. 9.89±4.5 mg/mL, p=0.043). ○ Zinc (0.61±0.14 vs. 0.67±0.15mg/L, p=0.016) Baum MK et al., 2011

Preliminary Study  Significantly increased glutathione peroxidase concentration as liver disease advanced, as measured by APRI (β= ; p=0.0082) and FIB-4 (β=0.0029; p=0.0177).  Vitamin A concentration significantly decreased (β= , p=0.0417) as APRI increased Baum MK et al., 2011

Objective  To assess the association between oxidative stress and liver fibrosis in HIV/HCV co-infected adults.  To compare markers of oxidative stress between HIV/HCV co-infected and HIV mono-infected adults.

Methods  Study Design: Cross-sectional  Cohorts: -35 HIV/HCV co-infected patients who had recently undergone a liver biopsy, & -101 HIV mono-infected patients  Exclusion Criteria HBV disease End stage liver disease Pregnancy Chronic Inflammatory Diseases Morbid obesity <40 years old >60 years old Uncontrolled viral load

Methods  Blood was collected for measures of oxidative stress, HIV and HCV disease progression: ○ Mitochondrial specific 8-hydroxy- deoxyguanosine (mt-specific 8-oxo-dG) ○ Malondialdehyde (MDA) ○ Reduced, oxidized and total glutathione ○ CD4 cell count and HIV viral load ○ HCV genotype and HCV viral load

Methods  Liver fibrosis and inflammation were assessed with liver biopsy and scored using the Metavir Liver Fibrosis Scale.  Liver fibrosis (0 to 4) 0 = no fibrosis 1 = portal fibrosis without septa 2 = few septa 3 = numerous septa without cirrhosis 4 = cirrhosis 31  Liver activity A0 = no histological activity A1 = mild activity A2 = moderate activity A3 = severe activity The French METAVIR Cooperative Study Group Bedossa P, et al., 1996.

Results Table1: Characteristics of the Population CharacteristicN=136 Age, (years±SD)48.58±5.64 Gender % (N) Male Female (83) (53) Race/Ethnicity % (N) White Non-Hispanic White Hispanic Black Non-Hispanic Black Hispanic American Indian Other 3.36 (4) (28) (74) 5.04 (6) 1.68 (2) 4.28 (5) BMI (kg/m 2 ±SD)27.88±5.48 CD4 Cell Count (cells/µL±SD)532.59± HIV Viral Load (copies/mL±SD2,722.97±11, HCV Viral Load (copies /mL±SD (HIV/HCV co-infected, N=35) 9,286,462.35±12,057, % genotype 1a 59.65% genotype 1b

Results  Table 2: Frequencies of Liver Fibrosis and Activity Scores Liver Fibrosis Score%(N) Liver Activity Score%(N) A0 A1 A2 A

Results (N=136) VariableHIV Mono-Infected Mean±SD HIV/HCV Co-Infected Mean±SD p-Value MDA (µM)0.586± ± oxo-dG (∆Ct)0.743± ± * Reduced Glutathione Concentration (µM) ± ± Reduced Glutathione/Total Glutathione Ratio (%) 77.59± ± Oxidized Glutathione Concentration (µM) ± ± Oxidized Glutathione/Total Glutathione Ratio (%) 22.45± ± Table 3: Difference In Mean Measures Of Oxidative Stress Between HIV Mono-Infected And HV/HCV Co-Infected Participants *Statistically significant, p<0.05

Results Low Fibrosis scores were significantly associated with lower levels of 8-oxo-dG (β=0.391, p=0.05,) than high fibrosis scores in HIV/HCV Co-Infection Fibrosis 8-oxo-dG (∆Ct) p=0.05 β=0.391 The grade of inflammation was positively and strongly associated with oxidized (GSSG) glutathione (β=0.0034, p=0.002).

Results  Using linear regression, HCV viral load was positively associated with 8-oxo-dG (β=1.18, p=0.042) after controlling for age, race, and BMI. Relationship between HCV Viral Load and 8-oxo-dG 8-oxo-dG (∆Ct)

Results  Using linear regression, HCV viral load was positively associated with MDA (β=3.97, p=0.049) after controlling for BMI. Relationship between HCV Viral Load and MDA

Discussion/Conclusions  HIV/HCV co-infection in our study was associated with pro-oxidative environment; higher oxidative stress correlated with higher fibrosis & inflammation scores, and higher HCV viral load.  Oxidative stress induces proliferation of hepatic stellate cells, TGF-β and collagen synthesis. 9, 31, 33  Oxidative stress participates in the development of progression to fibrosis in patients with Hepatitis C. 31, 32, Leonardo A, et al, Moriya K, et al, Choi J & Ou JH, 2006

Discussion/ Conclusions  Evidence suggests that antioxidants effectively attenuate the oxidative liver injury, & improve inflammation & fibrosis progression in HCV: Normalization of liver enzymes, histological improvement & reduction of HCV viral load was observed in a significant proportion of patients with chronic HCV using a combination antioxidant therapy. 34,35 However, antioxidant resveratrol enhanced the HCV replication in vitro. 36  Strategies to limit HIV/HCV induction of oxidative stress are warranted to slow hepatic fibrosis. Antioxidants need to be tested for their effects on HCV replication. 34. Melhem A, et al, Gabbay E, et al., Nakamura M, et al, 2010

Collaborators  Florida International University Marianna K Baum, PhD Adriana Campa, PhD Dong-Ho Shin, PhD Sabrina Sales Martinez, MS Yinghui Li, MS  University of Miami Dushyantha T Jayaweera, MD Victor J Casillas, MD Funded by NIDA grant # R01DA & D-CFAR, University of Miami The project was supported by Award Number R01DA from the National Institute On Drug Abuse. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute On Drug Abuse or the National Institutes of Health.